- Home
- CTSH vs MRNA Comparison
CTSH vs MRNA Comparison
Compare CTSH & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTSH | MRNA |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4B | 21.6B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CTSH | MRNA |
|---|---|---|
| Price | $53.15 | $47.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | ★ $80.47 | $34.27 |
| AVG Volume (30 Days) | ★ 8.1M | 6.8M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | 1.11 | ★ 21.77 |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $21,108,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $8.17 | $9.36 |
| Revenue Next Year | $5.06 | $15.43 |
| P/E Ratio | $38.43 | ★ N/A |
| Revenue Growth | ★ 6.95 | 4.29 |
| 52 Week Low | $45.48 | $22.28 |
| 52 Week High | $87.03 | $59.55 |
Technical Indicators
Market Signals| Indicator | CTSH | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 45.61 |
| Support Level | $45.48 | $46.13 |
| Resistance Level | $62.66 | $55.36 |
| Average True Range (ATR) | 2.31 | 2.65 |
| MACD | 0.53 | 0.18 |
| Stochastic Oscillator | 56.22 | 35.25 |
Price Performance
Historical ComparisonAbout CTSH Cognizant Technology Solutions Corporation
Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.